Intermediate filament reactivity in hyperplastic and neoplastic lesions from medaka (Oryzias latipes).
To determine if hyperplastic and neoplastic lesions from medaka showed similar immunoreactivity to intermediate filament antibodies as the tissues of origin, two week old medaka were exposed to 10 or 20 mg/L of methylazoxymethanol acetate for two hours and transferred to clean water for up to six months. Using a streptavidin peroxidase method, paraffin embedded Bouins fixed neoplasms were incubated with cytokeratin, vimentin, or neurofilament antibodies. Like their nonneoplastic cellular counterparts, hepatocellular carcinoma, pancreatic acinar carcinoma and mesenchymal neoplasms including hemangioma and hemangiopericytoma reacted negatively to cytokeratin antibodies. Cholangiocarcinoma, mesothelioma, and proliferative lesions containing biliary epithelial cells reacted positively to cytokeratin antibodies. All neoplasms and proliferative lesions were negative with vimentin and neurofilament antibodies. These data indicate that while some epithelial neoplasms showed cytokeratin reactivity similar to the parent tissues, additional markers are needed to identify mesenchymal tissues and neoplasms.
Bunton
T E
TE
Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
D018248:Adenoma, Liver Cell / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D000818:Animals; D000906:Antibodies / Q000032:analysis / Q000276:immunology; D002273:Carcinogens; D018267:Carcinoma, Acinar Cell / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D002455:Cell Division; D018281:Cholangiocarcinoma / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006391:Hemangioma / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006393:Hemangiopericytoma / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006965:Hyperplasia / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D007150:Immunohistochemistry; D007382:Intermediate Filaments / Q000737:chemistry / Q000276:immunology* / Q000648:ultrastructure; D007633:Keratins / Q000032:analysis / Q000276:immunology; D008099:Liver / Q000276:immunology / Q000473:pathology*; D008113:Liver Neoplasms / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D008746:Methylazoxymethanol Acetate / Q000031:analogs & derivatives; D016900:Neurofilament Proteins / Q000032:analysis / Q000276:immunology; D009990:Oryzias; D010179:Pancreas / Q000276:immunology / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D014746:Vimentin / Q000032:analysis / Q000276:immunology
D000906:Antibodies; D002273:Carcinogens; D016900:Neurofilament Proteins; D014746:Vimentin; D008746:Methylazoxymethanol Acetate; D007633:Keratins; C030667:methylazoxymethanol